Organovo Holdings Inc
ONVO
Company Profile
Business description
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
Contact
11555 Sorrento Valley road
Suite 100
San DiegoCA92121
USAT: +1 858 224-1000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2025
Employees
20
Stocks News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
stocks
What next for Tesla as 2024 deliveries disappoint?
Tesla shares started the year on a sour note. We think they continue to price in ambitious growth going forward.
stocks
Best and worst performing ASX sectors of 2024
Exploring the ASX sectors that moved the market this year.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,516.50 | 4.60 | 0.05% |
| CAC 40 | 7,445.69 | 163.47 | 2.24% |
| DAX 40 | 20,216.19 | 310.11 | 1.56% |
| Dow JONES (US) | 42,682.74 | 49.39 | -0.12% |
| FTSE 100 | 8,249.66 | 25.68 | 0.31% |
| HKSE | 19,688.29 | 71.98 | -0.36% |
| NASDAQ | 19,817.14 | 195.46 | 1.00% |
| Nikkei 225 | 39,307.05 | 587.49 | -1.47% |
| NZX 50 Index | 13,072.93 | 5.10 | 0.04% |
| S&P 500 | 5,969.06 | 26.59 | 0.45% |
| S&P/ASX 200 | 8,257.40 | 6.90 | 0.08% |
| SSE Composite Index | 3,206.92 | 4.51 | -0.14% |